Upgrade to SI Premium - Free Trial

Dianthus Therapeutics (DNTH)

80.51 -3.62 (4.30%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (5/5/26 *Est.)

Latest Headlines

Form 4 Dianthus Therapeutics, For: Jun 01 Filed by: Randhawa Simrat June 2, 2026 7:00 PM - SEC Filing Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 2, 2026 4:01 PM - Globe NewsWire Form 144 Dianthus Therapeutics, Filed by: Randhawa Simrat June 1, 2026 4:14 PM - SEC Filing Dianthus Therapeutics to Participate in Two Investor Conferences May 26, 2026 4:01 PM - Globe NewsWire Form 4 Dianthus Therapeutics, For: May 21 Filed by: McGeorge Anne May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Read Simon May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Lawton Alison Frances May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Romano Steven J. May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Violin Jonathan May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Soteropoulos Paula May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: KANGO SUJAY May 22, 2026 4:30 PM - SEC Filing Form 8-K Dianthus Therapeutics, For: May 21 May 22, 2026 4:10 PM - SEC Filing Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases May 19, 2026 3:00 PM - Globe NewsWire Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P. May 15, 2026 4:46 PM - SEC Filing Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Point72 Asset Management, L.P. May 15, 2026 4:34 PM - SEC Filing Form SCHEDULE 13G Dianthus Therapeutics, Filed by: Sirenia Capital Management LP May 15, 2026 8:14 AM - SEC Filing Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP May 15, 2026 7:25 AM - SEC Filing Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Octagon Capital Advisors LP May 14, 2026 4:02 PM - SEC Filing Intellia short interest rises most among biotech stocks in latest period - Baird May 12, 2026 9:58 AM - StreetInsider Form 4 Dianthus Therapeutics, For: May 08 Filed by: Soteropoulos Paula May 11, 2026 5:00 PM - SEC Filing LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis May 5, 2026 10:57 PM - Globe NewsWire Dianthus Therapeutics (DNTH) Misses Q1 EPS by 85c May 5, 2026 5:27 PM - StreetInsider Form 10-Q Dianthus Therapeutics, For: Mar 31 May 5, 2026 4:08 PM - SEC Filing Form 8-K Dianthus Therapeutics, For: May 05 May 5, 2026 4:04 PM - SEC Filing Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results May 5, 2026 4:01 PM - Globe NewsWire Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 1, 2026 4:30 PM - Globe NewsWire Form SCHEDULE 13G Dianthus Therapeutics, Filed by: BlackRock, Inc. April 27, 2026 4:14 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Apr 09 Filed by: Savitz Ryan April 10, 2026 4:52 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan April 9, 2026 4:23 PM - SEC Filing Form ARS Dianthus Therapeutics, For: Dec 31 April 9, 2026 4:12 PM - SEC Filing Form DEFA14A Dianthus Therapeutics, April 9, 2026 4:11 PM - SEC Filing Form DEF 14A Dianthus Therapeutics, For: May 21 April 9, 2026 4:09 PM - SEC Filing Wolfe Research Starts Dianthus Therapeutics (DNTH) at Outperform April 8, 2026 4:32 PM - StreetInsider Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 6, 2026 4:01 PM - Globe NewsWire Form 4 Dianthus Therapeutics, For: Mar 31 Filed by: Savitz Ryan April 1, 2026 5:27 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Mar 31 Filed by: Soteropoulos Paula April 1, 2026 5:26 PM - SEC Filing William Blair Shuffles Analyst Conviction List for April 2026 April 1, 2026 7:15 AM - StreetInsider Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan March 31, 2026 4:25 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Soteropoulos Paula March 31, 2026 4:21 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Mar 24 Filed by: Soteropoulos Paula March 26, 2026 6:00 PM - SEC Filing William Blair on Dianthus Therapeutics (DNTH): FDA removing ANA criteria 'an incremental positive' March 26, 2026 10:54 AM - StreetInsider Form 8-K Dianthus Therapeutics, For: Mar 26 March 26, 2026 8:01 AM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Soteropoulos Paula March 24, 2026 4:30 PM - SEC Filing Wells Fargo Reiterates Overweight Rating on Dianthus Therapeutics (DNTH) March 19, 2026 5:23 AM - StreetInsider Form 4 Dianthus Therapeutics, For: Mar 16 Filed by: Garcia Marino March 17, 2026 5:23 PM - SEC Filing William Blair Reiterates Outperform Rating on Dianthus Therapeutics (DNTH): 'should see multiple value inflection for shares' March 16, 2026 10:09 AM - StreetInsider Form 4 Dianthus Therapeutics, For: Mar 12 Filed by: CARR EDWARD March 13, 2026 8:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Mar 12 Filed by: Randhawa Simrat March 13, 2026 8:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: Mar 12 Filed by: Garcia Marino March 13, 2026 8:30 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Garcia Marino March 12, 2026 4:59 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Randhawa Simrat March 12, 2026 4:30 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: CARR EDWARD March 12, 2026 4:26 PM - SEC Filing Dianthus Therapeutics completes $719 million public offering March 12, 2026 4:01 PM - StreetInsider Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares March 12, 2026 4:01 PM - Globe NewsWire Form 8-K Dianthus Therapeutics, For: Mar 10 March 12, 2026 7:20 AM - SEC Filing Form 424B5 Dianthus Therapeutics, March 11, 2026 5:32 PM - SEC Filing Dianthus Therapeutics prices $625 million public stock offering March 10, 2026 10:54 PM - StreetInsider Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering March 10, 2026 10:54 PM - Globe NewsWire Form S-3MEF Dianthus Therapeutics, March 10, 2026 9:55 PM - SEC Filing Dianthus Therapeutics (DNTH) PT Raised to $130 at H.C. Wainwright March 10, 2026 7:21 AM - StreetInsider Dianthus Therapeutics (DNTH) PT Raised to $132 at Baird March 10, 2026 6:27 AM - StreetInsider Raymond James Upgrades Dianthus Therapeutics (DNTH) to Strong Buy March 10, 2026 4:16 AM - StreetInsider Dianthus Therapeutics (DNTH) PT Raised to $130 at Clear Street March 9, 2026 5:28 PM - StreetInsider Form 424B5 Dianthus Therapeutics, March 9, 2026 5:26 PM - SEC Filing Dianthus Therapeutics announces $400 million public stock offering March 9, 2026 4:01 PM - StreetInsider Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering March 9, 2026 4:01 PM - Globe NewsWire Dianthus Therapeutics (DNTH) PT Raised to $98 at Jefferies March 9, 2026 3:51 PM - StreetInsider Dianthus Therapeutics (DNTH) 1300 contracts of May 70 puts trade, share price up 19.3% March 9, 2026 2:55 PM - StreetInsider TD Cowen Reiterates Buy Rating on Dianthus Therapeutics (DNTH): "prime takeout target" March 9, 2026 11:49 AM - StreetInsider Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer March 9, 2026 10:15 AM - StreetInsider Dianthus Therapeutics (DNTH) PT Raised to $120 at Stifel March 9, 2026 10:14 AM - StreetInsider Form S-8 Dianthus Therapeutics, March 9, 2026 9:05 AM - SEC Filing William Blair Reiterates Outperform Rating on Dianthus Therapeutics (DNTH): "remain bullish here" March 9, 2026 8:11 AM - StreetInsider Guggenheim Reiterates Buy Rating on Dianthus Therapeutics (DNTH): Phase 3 "results exceeded our expectations" March 9, 2026 8:09 AM - StreetInsider Dianthus Therapeutics (DNTH) Misses Q4 EPS by 143c March 9, 2026 7:44 AM - StreetInsider Clear Street on Dianthus Therapeutics (DNTH): 'We view these data as de-risking' March 9, 2026 7:28 AM - StreetInsider Dianthus Therapeutics (DNTH) PT Raised to $110 at Truist Securities March 9, 2026 7:26 AM - StreetInsider Stifel on Dianthus Therapeutics (DNTH): 'today's update represents a best-case outcome, in our view' March 9, 2026 7:25 AM - StreetInsider Form 10-K Dianthus Therapeutics, For: Dec 31 March 9, 2026 7:22 AM - SEC Filing Form 8-K Dianthus Therapeutics, For: Mar 09 March 9, 2026 7:19 AM - SEC Filing Dianthus Therapeutics advances Phase 3 CIDP trial early March 9, 2026 7:09 AM - StreetInsider Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results March 9, 2026 7:09 AM - Globe NewsWire Dianthus Therapeutics reaches early go decision in CIDP trial March 9, 2026 7:01 AM - StreetInsider Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) March 9, 2026 7:00 AM - Globe NewsWire Dianthus Therapeutics schedules call on CIDP trial results March 8, 2026 5:00 PM - StreetInsider Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneu March 8, 2026 5:00 PM - Globe NewsWire Full Article List